2,3 Dimercapto-1-propanol inhibits HIV-1 tat activity, viral production, and infectivity in vitro.
We have examined the effect of 2,3 dimercapto-1-propanol (DMP), which is known as an anti-heavy metal-poisoning drug, against human immunodeficiency virus type 1 (HIV-1). We demonstrate that DMP inhibited transactivation directed by tat protein, which is a metal containing transcriptional transactivating factor and also interfered with viral production. Furthermore, treatment and pretreatment of cells with DMP strongly reduced their sensitivity for HIV-1 infection through unknown mechanisms. These results indicate that DMP reveals pleuripotent effects on HIV-1 infection and production in vitro and thus may provide an exploitable hypothesis for designing new drugs against AIDS.
Institute for Virus Research, Kyoto University, Japan.
S
S
Kubota
M A
MA
el-Farrash
M
M
Maki
S
S
Harada
M
M
Hatanaka
D000595:Amino Acid Sequence; D000818:Animals; D002460:Cell Line; D004112:Dimercaprol / Q000494:pharmacology*; D015696:Gene Products, tat / Q000502:physiology*; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics / Q000502:physiology; D008969:Molecular Sequence Data; D015534:Trans-Activators / Q000502:physiology*; D015533:Transcriptional Activation / Q000187:drug effects*; D014779:Virus Replication; D054322:tat Gene Products, Human Immunodeficiency Virus
D015696:Gene Products, tat; D015534:Trans-Activators; D054322:tat Gene Products, Human Immunodeficiency Virus; D004112:Dimercaprol